Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab and Allergen Immunotherapy for Ragweed Allergy
NCT00078195Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2003
- Primary completion
- May 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omalizumab in seasonal allergic rhinitis (SAR) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Average daily allergy severity score. Started Apr 2003; status: completed.
02
Drugs
omalizumab
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00078195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078195.